Table 1 Estimation of intactness or integrity of transcript length using reverse transcriptase mediated cDNA preparation using 3’ end followed by region specific PCR
Tumor type (Reference) | Transcript examined in exosomal RNA | Full length mRNA (bp) | Nucleotide position showing amplification | Product length (bp) | Transcript coverage (nt) |
|---|---|---|---|---|---|
Glioblastoma [14] | GAPDH | 1231 | 82-256 | 175 | 1150 |
EGFR/EGFRvIII PCR1 | 1575 | 216-1447 | 1232 | 1360 | |
EGFR/EGFRvIII PCR2 | 1775 | 262-1414 | 1153 | 1514 | |
Colorectal cancer [20] | β-actin | 1812 | 353-479 | 127 | 1460 |
β-catenin (CTNNB1) | 3488 3197 | 206-471 206-339 | 266 134 | 3283 2992 | |
RAB13 | 1164 | 182-254 | 73 | 983 | |
CXCR4 | 1904 | 116-188 | 73 | 1789 | |
MYC | 3721 | 371-440 | 70 | 3351 | |
Breast Cancer [21] | EEF1A1 | 3512 | 1329-1438 | 110 | 2184 |
FTH1 | 1203 | 440-573 | 134 | 764 | |
FTL | 871 | 384-529 | 146 | 488 | |
RAB13 | 1347 | 785-891 | 107 | 563 | |
RPL28 | 4209 | 215-338 | 124 | 3995 | |
Prostate cancer [49] | GAPDH | 1285 | 950-1050 | 101 | 336 |
Cervical cancer (present study) | β-actin | 1812 | 904-1171 | 268 | 908 |